Sutro Biopharma (NASDAQ: STRO) is poised to announce its financial results for the fourth quarter of 2025 on Thursday, March 12, 2026, prior to the market opening. Analysts anticipate the company will report a loss of ($4.66) per share alongside revenue of approximately $9.263 million for the quarter. The details for the conference call, scheduled for March 27, 2026, at 16:00 ET, are available on the company’s earnings report page.
Investors have shown keen interest in Sutro Biopharma’s stock performance, which opened at $24.98 on Tuesday. The firm carries a market capitalization of $212.58 million, with a price-to-earnings (P/E) ratio of -0.96 and a beta of 1.47. Recent trading has seen the stock fluctuate between a one-year low of $5.23 and a high of $26.54.
Analysts Provide Mixed Ratings on Sutro Biopharma
Several financial analysts have shared insights regarding Sutro Biopharma’s stock. On December 2, 2025, Wedbush maintained a “neutral” rating, significantly raising its price target from $20.00 to $100.00. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on December 17, 2025. HC Wainwright adjusted its price target upward to $10.00, maintaining a “neutral” stance on December 22, 2025. In contrast, Citigroup upgraded the stock to an “outperform” rating on January 20, 2026. The same day, Citizens JMP elevated its rating from “market perform” to “market outperform” with a price objective of $23.00.
As of now, analysts’ ratings include four “buy” recommendations, three “hold” ratings, and two “sell” ratings. According to data from MarketBeat, Sutro Biopharma has a consensus rating of “hold” with a target price averaging $31.83.
Hedge Fund Activity Reflects Growing Interest
Recent movements among hedge funds indicate increasing interest in Sutro Biopharma. Velan Capital Investment Management LP increased its stake by 2.0% during the third quarter, now holding 3,120,000 shares valued at approximately $2.709 million. UBS Group AG also expanded its holdings by 14.0%, acquiring an additional 226,955 shares, bringing its total to 1,845,839 shares, worth about $1.602 million.
AQR Capital Management LLC made a substantial move by boosting its holdings by an impressive 1,052.8%, now owning 1,320,917 shares valued at $859,000. Other hedge funds, including Jane Street Group LLC and Jacobs Levy Equity Management Inc., have also taken new positions in Sutro Biopharma.
Overall, institutional investors control nearly 97% of Sutro Biopharma’s stock, reflecting significant confidence in the company’s potential.
Sutro Biopharma, founded in 2003 and headquartered in South San Francisco, California, is a clinical-stage biopharmaceutical company dedicated to developing innovative biologic drug candidates in oncology and immunology. Its proprietary cell-free protein synthesis platform, XpressCFTM, allows for the rapid design and production of complex proteins, including antibody-drug conjugates and bispecific antibodies. This approach enables the development of therapeutics that may not be achievable through traditional methods.
As the earnings announcement approaches, stakeholders will be keenly watching Sutro Biopharma’s performance and the implications for its strategic direction.
